Gopsi Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 17-11-2024
- Paid Up Capital ₹ 0.99 M
as on 17-11-2024
- Company Age 27 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.60 Cr
as on 17-11-2024
- Revenue 8.69%
(FY 2023)
- Profit 164.49%
(FY 2023)
- Ebitda 113.89%
(FY 2023)
- Net Worth 40.01%
(FY 2023)
- Total Assets 10.32%
(FY 2023)
About Gopsi Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.99 M.
The company currently has active open charges totaling ₹1.60 Cr.
Baldevbhai Prajapati, Prajapati Baldevbhai, and Artiben Prajapati serve as directors at the Company.
- CIN/LLPIN
U24232GJ1997PTC031585
- Company No.
031585
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Jan 1997
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Gopsi Pharma Private Limited offer?
Gopsi Pharma Private Limited offers a wide range of products and services, including Chemical Reagents & Catalysts, Organic Compounds.
Who are the key members and board of directors at Gopsi Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Artiben Prajapati  | Director | 18-Feb-2015 | Current |
| Baldevbhai Prajapati | Director | 27-Jan-1997 | Current |
| Prajapati Baldevbhai | Director | 18-Feb-2015 | Current |
Financial Performance and Corporate Structure Insights of Gopsi Pharma.
Gopsi Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 8.69% increase. The company also saw a substantial improvement in profitability, with a 164.49% increase in profit. The company's net worth Soared by an impressive increase of 40.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gopsi Pharma?
In 2022, Gopsi Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 10 Mar 2022 | ₹1.00 Cr | Open |
Others Creation Date: 27 Mar 2019 | ₹5.00 M | Open |
Oriental Bank Of Commerce Creation Date: 16 Oct 2001 | ₹1.00 M | Open |
How Many Employees Work at Gopsi Pharma?
Unlock and access historical data on people associated with Gopsi Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gopsi Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gopsi Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
